Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 4
2005 2
2006 1
2007 2
2008 10
2009 3
2010 6
2011 6
2012 8
2013 8
2014 9
2015 8
2016 4
2017 7
2018 5
2019 6
2020 8
2021 12
2022 17
2023 9
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Results by year

Filters applied: . Clear all
Page 1
Editorial: Effector functions of therapeutic antibodies.
Boross P, Peipp M, Nimmerjahn F. Boross P, et al. Among authors: peipp m. Front Immunol. 2023 Jan 12;13:1126966. doi: 10.3389/fimmu.2022.1126966. eCollection 2022. Front Immunol. 2023. PMID: 36713416 Free PMC article. No abstract available.
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, Mutis T, Bleeker WK, Anderson KC, Lokhorst HM, van de Winkel JG, Parren PW. de Weers M, et al. Among authors: peipp m. J Immunol. 2011 Feb 1;186(3):1840-8. doi: 10.4049/jimmunol.1003032. Epub 2010 Dec 27. J Immunol. 2011. PMID: 21187443 Clinical Trial.
Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells.
Lutz S, Klausz K, Albici AM, Ebinger L, Sellmer L, Teipel H, Frenzel A, Langner A, Winterberg D, Krohn S, Hust M, Schirrmann T, Dübel S, Scherließ R, Humpe A, Gramatzki M, Kellner C, Peipp M. Lutz S, et al. Among authors: peipp m. Front Immunol. 2023 Oct 27;14:1227572. doi: 10.3389/fimmu.2023.1227572. eCollection 2023. Front Immunol. 2023. PMID: 37965326 Free PMC article.
Complement in antibody-based tumor therapy.
Derer S, Beurskens FJ, Rosner T, Peipp M, Valerius T. Derer S, et al. Among authors: peipp m. Crit Rev Immunol. 2014;34(3):199-214. doi: 10.1615/critrevimmunol.2014009761. Crit Rev Immunol. 2014. PMID: 24941073 Review.
The relevance of complement in pemphigoid diseases: A critical appraisal.
Papara C, Karsten CM, Ujiie H, Schmidt E, Schmidt-Jiménez LF, Baican A, Freire PC, Izumi K, Bieber K, Peipp M, Verschoor A, Ludwig RJ, Köhl J, Zillikens D, Hammers CM. Papara C, et al. Among authors: peipp m. Front Immunol. 2022 Aug 16;13:973702. doi: 10.3389/fimmu.2022.973702. eCollection 2022. Front Immunol. 2022. PMID: 36059476 Free PMC article. Review.
Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis.
Vogiatzi F, Heymann J, Müller K, Winterberg D, Drakul A, Rösner T, Lenk L, Heib M, Gehlert CL, Cario G, Schrappe M, Claviez A, Bornhauser B, Bourquin JP, Bomken S, Adam D, Frielitz FS, Maecker-Kolhoff B, Stanulla M, Valerius T, Peipp M, Kellner C, Schewe DM. Vogiatzi F, et al. Among authors: peipp m. Blood Adv. 2022 Aug 23;6(16):4847-4858. doi: 10.1182/bloodadvances.2022007364. Blood Adv. 2022. PMID: 35820018 Free PMC article.
119 results